Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes

Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter:

”If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers! Amazing study led by Carmen Mecca.”

Source: Biagio Ricciuti/X

AACR AACR24 ALK-positive cancers American Association for Cancer Research Biagio Ricciuti cancer Carmen Mecca cell therapies Dana-Farber Cancer Institute OncoDaily Oncology TCR clonotypes